Biological: All AAV2, FIX-WT, AAV-hF.IX, NCT00076557 AAV2, FIX-WT, rAAV-hAAT-F.IX AAV5, FIX-Padua, Hemgenix, NCT03489291 AAV5, FIX-Padua, Hemgenix, NCT03569891 (Phase III, Hope-B Trial) AAV5, FIX-WT, AMT-060, uniQure, NCT02396342 AAV5, FVIII-BDD, Roctavian, NCT02576795 (Phase 1/2 Study) AAV5, FVIII-BDD, Roctavian, NCT03370913 (Phase 3, GENEr8-1 Study) AAV5, FVIII-BDD, Roctavian, NCT03370913 and NCT03392974, Data of Participants with HIV AAV6, FIX-WT, SB-FIX, NCT02695160 (No Results Published) AAV6, FVIII-BDD, Giroctocogene Fitelparvovec (SB-525), NCT03061201 (Phase 1/2) AAV6, FVIII-BDD, Giroctocogene Fitelparvovec (SB-525), NCT04370054 (Phase 3 study) AAV8, FIX-Padua, BAX 335, NCT01687608 AAV8, FIX-WT, scAAV2/8-LP1-hFIXco, NCT00979238 AAV8, FVIII-BDD, SHP654 (BAX 888), NCT03370172 AAV8, FVIII-V3, AAV2/8-HLP-FVIII-V3, NCT03001830 AAVhu37, FVIII-BDD, DTX201, NCT03588299 AAVrh10, FIX-WT, DTX101, NCT02618915 AAVS3, FIX-Padua, FLT180a, NCT03369444 AAV-Spark100, FIX-Padua, Fidanacogene elaparvovec (ᴾʳBEQVEZ™), NCT02484092 AAV-Spark100, FIX-Padua, Fidanacogene elaparvovec (ᴾʳBEQVEZ™), NCT03861273 (Phase 3, BeneGene-2) AAV-SPK200, FVIII-BDD, Dirloctocogene samoparvovec (SPK-8011), NCT03003533 and NCT03432520 Bioengineered AAV capsid, FVIII-BDD, SPK-8016, NCT03734588 and NCT03432520 LV, FVIII, YUVA-GT-F801, NCT03217032 (no results published) LV, FVIII-ET3, CD68-ET3-LV CD34+, Expression Therapeutics, NCT04418414 (no results published)

Sponsor: All Avigen¹/CHOP ² Baxalta now part of Shire Bayer/Ultragenyx BioMarin Pharmaceutical CSL Behring Dimension Therapeutics Expression Therapeutics, LLC Non-commercial Non-commercial, Avigen/CHOP Pfizer Pfizer/Sangamo Roche/Spark Therapeutics Sangamo Therapeutics Shenzhen Geno-Immune Medical Institute Shire Spark Therapeutics uniQure University College, London

Disorder: All Haemophilia A Haemophilia B